The most important clinical successes achieved in the ER ligand field over the past decades mainly involve SERMs or ERα antagonists which are used in the treatment of estrogen-related cancers such as breast cancer, osteoporosis, and cardiovascular diseases [47]. Here, ESR1 is linked to breast carcinoma.